Plasma concentrations of apolipoproteins A-I, B, and M in patients with critical limb ischemia

Clinical Biochemistry

Volumn 43, Issue 6, 2010, Pages 599-603

  Ahnström, Josefin ^a   Gottsäter, Anders ^b   Lindblad, Bengt ^b   Dahlback Bjorn B ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ApoA I; ApoB; ApoM; Atherosclerosis; Cholesterol; CLI; HDL; PAD; Peripheral arterial disease

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN M; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FOLLOW UP; GANGRENE; HUMAN; LEG ULCER; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; SURVIVAL RATE; TISSUE SECTION;

AGED; AGED, 80 AND OVER; APOLIPOPROTEIN A-I; APOLIPOPROTEINS; APOLIPOPROTEINS B; CASE-CONTROL STUDIES; CRITICAL ILLNESS; FEMALE; HUMANS; ISCHEMIA; LOWER EXTREMITY; MALE; OSMOLAR CONCENTRATION; PERIPHERAL VASCULAR DISEASES; SURVIVAL ANALYSIS;

EID: 77950866515     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.01.001     Document Type: Article

References (33)

1. Shammas N.W. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag 2007, 3:229-234.
2. Gottsater A. Managing risk factors for atherosclerosis in critical limb ischaemia. Eur J Vasc Endovasc Surg 2006, 32:478-483.
3. Novo S., Coppola G., Milio G. Critical limb ischemia: definition and natural history. Curr Drug Targets Cardiovasc Haematol Disord 2004, 4:219-225.
4. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007, 45(Suppl S):S5-67.
5. Arain F.A., Cooper L.T. Peripheral arterial disease: diagnosis and management. Mayo Clin Proc 2008, 83:944-949. quiz 949-50.
6. Boden W.E. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000, 86:19L-22L.
7. Goldbourt U., Yaari S., Medalie J.H. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997, 17:107-113.
8. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707-714.
9. Mensah G.A., Brown D.W., Croft J.B., Greenlund K.J. Major coronary risk factors and death from coronary heart disease: baseline and follow-up mortality data from the Second National Health and Nutrition Examination Survey (NHANES II). Am J Prev Med 2005, 29:68-74.
10. Bismuth J., Kofoed S.C., Jensen A.S., Sethi A., Sillesen H. Serum lipids act as inverse acute phase reactants and are falsely low in patients with critical limb ischemia. J Vasc Surg 2002, 36:1005-1010.
11. Isma N., Barani J., Mattiasson I., Lindblad B., Gottsater A. Lipid-lowering therapy is related to inflammatory markers and 3-year mortality in patients with critical limb ischemia. Angiology 2008, 59:542-548.
12. Sigvant B., Wiberg-Hedman K., Bergqvist D., Rolandsson O., Wahlberg E. Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease. Eur J Cardiovasc Prev Rehabil 2009, 16:39-46.
13. Barani J., Nilsson J.A., Mattiasson I., Lindblad B., Gottsater A. Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasc Surg 2005, 42:75-80.
14. Olofsson S.O., Wiklund O., Boren J. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag 2007, 3:491-502.
15. Sniderman A.D., Furberg C.D., Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003, 361:777-780.
16. Barter P.J., Rye K.A. The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med 2006, 259:447-454.
17. Xu N., Dahlback B. A novel human apolipoprotein (apoM). J Biol Chem 1999, 274:31286-31290.
18. Christoffersen C., Nielsen L.B., Axler O., Andersson A., Johnsen A.H., Dahlback B. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 2006, 47:1833-1843.
19. Ahnstrom J., Faber K., Axler O., Dahlback B. Hydrophobic ligand binding properties of the human lipocalin apolipoprotein M. J Lipid Res 2007, 48:1754-1762.
20. Sevvana M., Ahnstrom J., Egerer-Sieber C., Lange H.A., Dahlback B., Muller Y.A. Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M. J Mol Biol 2009, 393:920-936.
21. Axler O., Ahnstrom J., Dahlback B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res 2007, 48:1772-1780.
22. Ahnstrom J., et al. Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. J Lipid Res 2008, 49:1912-1917.
23. Christoffersen C., Jauhiainen M., Moser M., et al. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem 2008, 283:1839-1847.
24. Wolfrum C., Poy M.N., Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 2005, 11:418-422.
25. Ahnstrom J, Gottsater A, Lindblad B, Dahlback B. Plasma concentrations of apolipoproteins A-I, B and M in patients with abdominal aortic aneurysms. Clin Biochem. [Electronic publication ahead of print].
26. Barani J., Mattiasson I., Lindblad B., Gottsater A. Suboptimal treatment of risk factor for atherosclerosis in critical limb ischemia. Int Angiol 2005, 24:59-63.
27. Nilsson P., Berglund G. Prevention of cardiovascular disease and diabetes: lessons from the Malmo Preventive Project. J Intern Med 2000, 248:455-462.
28. Team, R.D.C. (2009) R: A Language and Environment for Statistical Computinged.^eds). R Foundation for Statistical Comuting, Vienna, Austria.
29. Van Lenten B.J., Reddy S.T., Navab M., Fogelman A.M. Understanding changes in high density lipoproteins during the acute phase response. Arterioscler Thromb Vasc Biol 2006, 26:1687-1688.
30. Feingold K.R., Shigenaga J.K., Chui L.G., Moser A., Khovidhunkit W., Grunfeld C. Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis 2008, 199:19-26.
31. Dullens S.P., Plat J., Mensink R.P. Increasing apoA-I production as a target for CHD risk reduction. Nutr Metab Cardiovasc Dis 2007, 17:616-628.
32. Nilsson-Ehle P. Energiomsättning. Laurells klinisk kemi i praktisk medicin 2003, 305-359. Studentliltteratur, Lund, Sweden. P. Nilsson-Ehle (Ed.).
33. Clyne B., Olshaker J.S. The C-reactive protein. J Emerg Med 1999, 17:1019-1025.